Literature DB >> 19943586

Defining the optimal therapy sequence in synchronous resectable liver metastases from colorectal cancer: a decision analysis approach.

E Van Dessel1, K Fierens, P Pattyn, Y Van Nieuwenhove, F Berrevoet, R Troisi, W Ceelen.   

Abstract

INTRODUCTION: Approximately 5%-20% of colorectal cancer (CRC) patients present with synchronous potentially resectable liver metastatic disease. Preclinical and clinical studies suggest a benefit of the 'liver first' approach, i.e. resection of the liver metastasis followed by resection of the primary tumour. A formal decision analysis may support a rational choice between several therapy options.
METHODS: Survival and morbidity data were retrieved from relevant clinical studies identified by a Web of Science search. Data were entered into decision analysis software (TreeAge Pro 2009, Williamstown, MA, USA). Transition probabilities including the risk of death from complications or disease progression associated with individual therapy options were entered into the model. Sensitivity analysis was performed to evaluate the model's validity under a variety of assumptions.
RESULTS: The result of the decision analysis confirms the superiority of the 'liver first' approach. Sensitivity analysis demonstrated that this assumption is valid on condition that the mortality associated with the hepatectomy first is < 4.5%, and that the mortality of colectomy performed after hepatectomy is < 3.2%.
CONCLUSION: The results of this decision analysis suggest that, in patients with synchronous resectable colorectal liver metastases, the 'liver first' approach is to be preferred. Randomized trials will be needed to confirm the results of this simulation based outcome.

Entities:  

Mesh:

Year:  2009        PMID: 19943586     DOI: 10.1080/00015458.2009.11680432

Source DB:  PubMed          Journal:  Acta Chir Belg        ISSN: 0001-5458            Impact factor:   1.090


  4 in total

1.  The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience.

Authors:  Mechteld C de Jong; Ronald M van Dam; Monique Maas; Marc H A Bemelmans; Steven W M Olde Damink; Geerard L Beets; Cornelis H C Dejong
Journal:  HPB (Oxford)       Date:  2011-09-05       Impact factor: 3.647

2.  Strategies for Management of Synchronous Colorectal Metastases.

Authors:  Jason A Castellanos; Nipun B Merchant
Journal:  Curr Surg Rep       Date:  2014-06-01

3.  Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure.

Authors:  Gerd R Silberhumer; Philip B Paty; Larissa K Temple; Raphael L C Araujo; Brian Denton; Mithat Gonen; Garret M Nash; Peter J Allen; Ronald P DeMatteo; Jose Guillem; Martin R Weiser; Michael I D'Angelica; William R Jarnagin; Douglas W Wong; Yuman Fong
Journal:  Am J Surg       Date:  2014-12-13       Impact factor: 2.565

4.  Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.

Authors:  Ajay S Behl; Katrina A B Goddard; Thomas J Flottemesch; David Veenstra; Richard T Meenan; Jennifer S Lin; Michael V Maciosek
Journal:  J Natl Cancer Inst       Date:  2012-11-28       Impact factor: 13.506

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.